InvestorsHub Logo
Followers 50
Posts 3284
Boards Moderated 0
Alias Born 05/25/2021

Re: Legend431 post# 616784

Wednesday, 08/02/2023 11:39:21 PM

Wednesday, August 02, 2023 11:39:21 PM

Post# of 673870
That's your wish to me? Doesn't seem like a good one.

Here is the figure I took from Dr. Bosch's present. Did you see the numbers I put in the figure to illustrate how many newly generated t-cells and how many expanded t-cells four and eight months after the vaccination. I downloaded a free software, extracted the data from the figure, and then put the numbers on the figure so that every true investor can have a clear idea on how extraordinary is the technology NWBO owns. How could you think I could end up holding bags? In the near future while I enjoy generational wealth, you are probably homeless.



Now look at this figure. Can you see how many tumor associated peptides that pulsed dendritic cells can present to t-cells? These are examples for illustrations. Most likely it was taken from one type of tumor.


Ever wonder how many types of tumors could have these peptides? Here are something you might want to know.

TRIM68 has been associated with:
1. Prostate Cancer: TRIM68 has been identified as a tumor suppressor in prostate cancer. It can inhibit cancer cell growth and invasion and is often downregulated in prostate cancer cells.
2. Colorectal Cancer: TRIM68 has been found to be downregulated in colorectal cancer, and its reduced expression is associated with cancer progression and poor prognosis.
3. Gastric Cancer: In gastric cancer, TRIM68 has been reported to act as a tumor suppressor, and its decreased expression is linked to cancer development and aggressiveness.
4. Breast Cancer: TRIM68 has been shown to inhibit breast cancer cell proliferation and migration, suggesting a potential tumor-suppressive role in breast cancer.
5. Lung Cancer: TRIM68 has been identified as a tumor suppressor in lung cancer. Its reduced expression is associated with poor survival in lung cancer patients.

Spermatogenesis-associated protein 2 (SPATA2)
1. Hepatocellular Carcinoma (Liver Cancer): Studies have shown that SPATA2 expression is upregulated in hepatocellular carcinoma, the most common form of liver cancer. Increased SPATA2 expression has been associated with tumor progression and poor prognosis in patients with hepatocellular carcinoma.
2. Colorectal Cancer: SPATA2 has been identified as a potential oncogene in colorectal cancer. Its overexpression in colorectal cancer cells has been linked to enhanced cancer cell growth and invasiveness.
3. Gastric Cancer: In gastric cancer, SPATA2 has been found to be upregulated and may contribute to cancer cell proliferation and migration.

Mammalian ependymin-related protein 1 (MERP1)
1. Breast Cancer: MERP1 has been found to be upregulated in breast cancer cells, and its expression is associated with tumor growth and metastasis. It has been suggested that MERP1 plays a role in promoting breast cancer cell survival and invasiveness.
2. Colorectal Cancer: Studies have shown that MERP1 expression is increased in colorectal cancer tissues. It is believed to contribute to cancer cell survival and drug resistance in colorectal cancer.
3. Hepatocellular Carcinoma (Liver Cancer): MERP1 has been identified as a potential biomarker for hepatocellular carcinoma. It is upregulated in liver cancer tissues, and its expression is associated with tumor progression and poor prognosis.
4. Lung Cancer: MERP1 has been found to be overexpressed in lung cancer cells. It may play a role in promoting cancer cell survival and resistance to chemotherapy.

Metallophosphoesterase 1 (MPP1)
1. hepatocellular carcinoma (Liver Cancer)

Agrin
1. Agrin Promotes Non-Small Cell Lung Cancer Progression and Stimulates Regulatory T Cells via Increasing IL-6 Secretion Through PI3K/AKT Pathway
2. Agrin regulates Blood Vessel Infiltration in Tumors

Integrin beta-4, also known as ITGB4
1. Squamous Cell Carcinoma: Integrin beta-4 is frequently overexpressed in squamous cell carcinoma (SCC), which is a type of skin cancer as well as certain other cancers such as esophageal squamous cell carcinoma. It has been associated with increased invasiveness and metastasis in SCC.
2. Breast Cancer: Integrin beta-4 has been found to be upregulated in breast cancer cells and is associated with a more aggressive phenotype and poor prognosis in some cases.
3. Colon Cancer: Integrin beta-4 has been implicated in colon cancer progression and metastasis.
4. Pancreatic Cancer: Integrin beta-4 expression has been linked to the invasive behavior of pancreatic cancer cells and may contribute to tumor aggressiveness.
5. Prostate Cancer: Integrin beta-4 has been identified as a potential biomarker for prostate cancer, and its expression has been associated with tumor progression.

Protein ABHD16B
1. Prostate Cancer: ABHD16B has been found to be upregulated in prostate cancer cells. It is involved in the hydrolysis of lysophosphatidylcholine (LPC) to produce lysophosphatidic acid (LPA), which is a bioactive lipid that promotes cancer cell proliferation, migration, and invasion. Elevated levels of ABHD16B have been linked to prostate cancer progression and aggressive behavior.
2. Ovarian Cancer: ABHD16B has also been identified as being upregulated in ovarian cancer tissues. Inhibition of ABHD16B has been shown to reduce ovarian cancer cell growth and migration, suggesting its potential role as a therapeutic target in ovarian cancer treatment.

Tyrosine-protein kinase Fes/Fps

Fes/Fps has also been linked to the development and progression of certain solid tumors:
1. Breast Cancer: Fes/Fps has been found to be overexpressed in some breast cancer tissues, and its increased expression is associated with tumor aggressiveness and poor prognosis.
2. Colorectal Cancer: Fes/Fps has been identified as a potential oncogene in colorectal cancer, and its upregulation is associated with increased cancer cell proliferation and metastasis.

Beta-actin-like protein 2
1. Actin beta-like 2 (ACTBL2) was found to be a putative risk gene in ovarian cancer

As I mentioned, this could most likely come from one tumor. How many types of solid tumors are there? If the same type of work as shown in Dr. Bosch's present is repeated for each type of solid tumor, can you imagine what would happen?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News